141 related articles for article (PubMed ID: 2305716)
1. Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
Sorio R; Tirelli U; Zagonel V; Carbone A; Monfardini S
Am J Clin Oncol; 1990 Feb; 13(1):14-6. PubMed ID: 2305716
[TBL] [Abstract][Full Text] [Related]
2. VM 26 in advanced mycosis fungoides.
Tirelli U; Carbone A; Tumolo S; Galligioni E; Veronesi A; Trovò MG; Grigoletto E
Tumori; 1981 Oct; 67(5):487-90. PubMed ID: 7324177
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
[TBL] [Abstract][Full Text] [Related]
4. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
5. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.
Giaccone G; Donadio M; Bonardi G; Testore F; Calciati A
J Clin Oncol; 1988 Aug; 6(8):1264-70. PubMed ID: 2842464
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy of cutaneous T-cell lymphomas with arotinoid].
Mahrle G; Thiele B; Ippen H
Dtsch Med Wochenschr; 1983 Nov; 108(46):1753-7. PubMed ID: 6605844
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
[TBL] [Abstract][Full Text] [Related]
9. A case of small cell lung cancer successfully treated with VM26.
Suga J; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Sakurai M; Sano T; Tamura T; Morinaga S
Jpn J Clin Oncol; 1986 Jun; 16(2):123-8. PubMed ID: 3016377
[TBL] [Abstract][Full Text] [Related]
10. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas.
Serri F; De Simone C; Venier A; Rusciani L; Marchetti F
Curr Probl Dermatol; 1990; 19():252-7. PubMed ID: 2404681
[No Abstract] [Full Text] [Related]
11. Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C; Matutes E; Catovsky D
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma.
Vonderheid EC; Tan ET; Kantor AF; Shrager L; Micaily B; Van Scott EJ
J Am Acad Dermatol; 1989 Mar; 20(3):416-28. PubMed ID: 2537348
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
14. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
15. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
Duvic M; Talpur R; Wen S; Kurzrock R; David CL; Apisarnthanarax N
Clin Lymphoma Myeloma; 2006 Jul; 7(1):51-8. PubMed ID: 16879770
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of teniposide in advanced breast cancer.
Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
[TBL] [Abstract][Full Text] [Related]
19. VM26 in malignant hematological diseases. A phase II study.
Tirelli U; Carbone A; Franchin G; Galligioni E; Veronesi A; Trovo MG; Volpe R; Tumolo S; Grigoletto E
Cancer Chemother Pharmacol; 1982; 7(2-3):173-4. PubMed ID: 6952964
[TBL] [Abstract][Full Text] [Related]
20. Teniposide (VM26) as second-line treatment for small cell lung cancer.
Tummarello D; Guidi F; Torresi U; Dazzi C; Cellerino R
Anticancer Res; 1990; 10(2A):397-9. PubMed ID: 2161198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
